1887

Abstract

Purpose. Extracellular protein toxins contribute to the pathogenesis of Staphylococcus aureus infections. The present study compared the effects of iclaprim and trimethoprim – two folic acid synthesis inhibitors – with nafcillin and vancomycin on production of Panton–Valentine leukocidin (PVL), alpha haemolysin (AH) and toxic-shock syndrome toxin I (TSST-1) in methicillin-resistant and vancomycin-intermediate S. aureus (MRSA and VISA, respectively).

Methodology. Northern blotting and RT-PCR were used to assess gene transcription; toxin-specific bioassays were used to measure protein toxin production.

Results. As shown previously, sub-inhibitory concentrations (sub-MIC) of nafcillin increased and prolonged MRSA toxin gene transcription and enhanced PVL, TSST-1 and AH production. Sub-inhibitory doses of iclaprim and trimethoprim delayed maximal AH gene (hla) transcription and suppressed AH production; both drugs delayed, but neither reduced, maximal TSST-1 production. Trimethoprim significantly increased lukF-PV expression and PVL production compared to both untreated and iclaprim-treated cultures. Higher concentrations of iclaprim and trimethoprim markedly suppressed MRSA growth, mRNA synthesis and toxin production. In VISA, iclaprim, vancomycin and nafcillin variably increased tst and hla expression, but only nafcillin increased toxin production. Despite its ability to increase hla expression, iclaprim was the most potent inhibitor of AH production.

Conclusions. We conclude that, due to its ability to suppress toxin production, iclaprim should be effective against severe staphylococcal infections caused by toxin-producing MRSA and VISA strains, especially given its ability to concentrate at sites of infection such as skin and skin structures and the lung.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000929
2019-01-24
2024-12-06
Loading full text...

Full text loading...

/deliver/fulltext/jmm/68/3/456.html?itemId=/content/journal/jmm/10.1099/jmm.0.000929&mimeType=html&fmt=ahah

References

  1. Gleckman R, Blagg N, Joubert DW. Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy 1981; 1:14–19 [View Article]
    [Google Scholar]
  2. Hartman PG. Molecular aspects and mechanism of action of dihydrofolate reductase inhibitors. J Chemother 1993; 5:369–376
    [Google Scholar]
  3. Entenza JM, Haldimann A, Giddey M, Lociuro S, Hawser S et al. Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model. Antimicrob Agents Chemother 2009; 53:3635–3641 [View Article]
    [Google Scholar]
  4. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195:202–211 [View Article]
    [Google Scholar]
  5. Hamilton SM, Bryant AE, Carroll KC, Lockary V, Ma Y et al. In vitro production of Panton-Valentine Leukocidin (PVL) among strains of methicillin-resistant Staphylococcus aureus causing diverse infections. Clin Infect Dis 2007; 45:1550–1558
    [Google Scholar]
  6. Li Z, Stevens DL, Hamilton SM, Parimon T, Ma Y et al. Fatal S. aureus hemorrhagic pneumonia: genetic analysis of a unique clinical isolate producing both PVL and TSST-1. PLoS One 2011; 6:e27246 [View Article]
    [Google Scholar]
  7. Diep BA, Sensabaugh GF, Somboona NS, Carleton HA, Perdreau-Remington F. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol 2004; 42:2080–2084 [View Article]
    [Google Scholar]
  8. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135–136 [View Article]
    [Google Scholar]
  9. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing. sixteenth informational supplement Wayne, PA: 2006M100–S16
    [Google Scholar]
  10. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359:1819–1827 [View Article]
    [Google Scholar]
  11. Sakoulas G, Eliopoulos GM, Moellering RC, Wennersten C, Venkataraman L et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492–1502 [View Article]
    [Google Scholar]
  12. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, NCCLS Approved standard. 2003M7–06
    [Google Scholar]
  13. Gemmell CG, Peterson PK, Schmeling DJ, Quie PG. Effect of staphylococcal alpha-toxin on phagocytosis of staphylococci by human polymorphonuclear leukocytes. Infect Immun 1982; 38:975–980
    [Google Scholar]
  14. Kernodle DS, McGraw PA, Barg NL, Menzies BE, Voladri RK et al. Growth of Staphylococcus aureus with nafcillin in vitro induces alpha-toxin production and increases the lethal activity of sterile broth filtrates in a murine model. J Infect Dis 1995; 172:410–419 [View Article]
    [Google Scholar]
  15. Lominski I, Arbuthnott JP. Some characteristics of Staphylococcus alpha hæmolysin. J Pathol 1962; 83:515–520 [View Article]
    [Google Scholar]
  16. van Langevelde P, van Dissel JT, Meurs CJ, Renz J, Groeneveld PH. Combination of flucloxacillin and gentamicin inhibits toxic shock syndrome toxin 1 production by Staphylococcus aureus in both logarithmic and stationary phases of growth. Antimicrob Agents Chemother 1997; 41:1682–1685 [View Article]
    [Google Scholar]
  17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001; 25:402–408 [View Article]
    [Google Scholar]
  18. Ohta T, Hirakawa H, Morikawa K, Maruyama A, Inose Y. Nucleotide substitutions in Staphylococcus aureus strains, Mu50, Mu3, and N315. DNA Res 2004; 11:51–56 [View Article]
    [Google Scholar]
  19. Brook I. Inoculum effect. Rev Infect Dis 1989; 11:361–368 [View Article]
    [Google Scholar]
  20. Holm SE, Tornqvist IO, Cars O. Paradoxical effects of antibiotics. Scand J Infect Dis Suppl 1990; 74:113–117
    [Google Scholar]
  21. Stevens DL, Van S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993; 167:1401–1405 [View Article]
    [Google Scholar]
  22. Aldape MJ, Packham AE, Nute DW, Bryant AE, Stevens DL. Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile. J Med Microbiol 2013; 62:741–747 [View Article]
    [Google Scholar]
  23. Stevens DL, Maier KA, Mitten JE. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987; 31:213–218 [View Article]
    [Google Scholar]
  24. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases Society of America. Clin Infect Dis 2014; 59:e10–e52
    [Google Scholar]
  25. Oefner C, Bandera M, Haldimann A, Laue H, Schulz H et al. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J Antimicrob Chemother 2009; 63:687–698 [View Article]
    [Google Scholar]
  26. Holland TL, O'Riordan W, McManus A, Shin E, Borghei A et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous Iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens (REVIVE-2 study). Antimicrob Agents Chemother 2018; 62:e02580–17 [View Article]
    [Google Scholar]
  27. Huang DB, O'Riordan W, Overcash JS, Heller B, Amin F et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens: REVIVE-1. Clin Infect Dis 2018; 66:1222–1229 [View Article]
    [Google Scholar]
  28. Rohlman CE, Matthews RG. Role of purine biosynthetic intermediates in response to folate stress in Escherichia coli. J Bacteriol 1990; 172:7200–7210 [View Article]
    [Google Scholar]
  29. Spriggs KA, Bushell M, Willis AE. Translational regulation of gene expression during conditions of cell stress. Mol Cell 2010; 40:228–237 [View Article]
    [Google Scholar]
  30. Babitzke P, Gollnick P. Posttranscription initiation control of tryptophan metabolism in Bacillus subtilis by the trp RNA-binding attenuation protein (TRAP), anti-TRAP, and RNA structure. J Bacteriol 2001; 183:5795–5802 [View Article]
    [Google Scholar]
  31. Fernandez J, Yaman I, Huang C, Liu H, Lopez AB et al. Ribosome stalling regulates IRES-mediated translation in eukaryotes, a parallel to prokaryotic attenuation. Mol Cell 2005; 17:405–416 [View Article]
    [Google Scholar]
  32. Huang DB, File TM, Dryden M, Corey GR, Torres A et al. Surveillance of iclaprim activity: in vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe. Diagn Microbiol Infect Dis 2018; 90:329–334 [View Article]
    [Google Scholar]
  33. Huang DB, Hawser S, Gemmell CG, Sahm DF. In vitro activity of Iclaprim against methicillin-resistant Staphylococcus aureus nonsusceptible to daptomycin, linezolid, or vancomycin: a pilot study. Can J Infect Dis Med Microbiol 2017epub 2017 Dec 17 [View Article]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.000929
Loading
/content/journal/jmm/10.1099/jmm.0.000929
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error